Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress
Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress
Jaguar continues its sharp strategic focus on its global development program for crofelemer for rare-disease intestinal failure (IF) indications; all patients with microvillus inclusion disease (MVID) suffer from IF, as do a significant proportion of patients with short bowel syndrome (SBS). The global market for SBS, including IF, is estimated to reach approximately $8.0 billion by 2033.
Near-term milestones for intestinal failure program buttressed by groundbreaking results of parenteral support reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric IF patients; Abstract for long-term safety and efficacy of crofelemer liquid formulation submitted for presentation at ESPGHAN (European Society for Paediatric Gastroenterology Hepatology and Nutrition) Annual Meeting in 2026.
Click here to view video update from Jaguar CEO Lisa Conte on company's near-term catalysts.
SAN FRANCISCO, CA / ACCESS Newswire / April 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that it is a silver-level sponsor of the April 2-4, 2026 Annual ELITE PED-GI Congress in Abu Dhabi in the United Arab Emirates (UAE).
As previously announced, Napo is supporting an independent investigator-initiated proof-of-concept study of crofelemer liquid formulation in pediatric intestinal failure (IF) patients with in microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) at Sheikh Khalifa Medical City in Abu Dhabi, UAE. The study's principal investigator, Dr. Mohamad Miqdady, previously presented an update on this study at the April 2025 ELITE PED-GI Congress, and patients participating in the study have continued to receive crofelemer treatment for more than one year.
Intestinal failure is a debilitating condition that often requires patients to receive life-sustaining fluids, electrolytes and nutrients through intravenous administration, which consists of total parenteral nutrition (TPN) with supplemental intravenous fluids, which together constitute PS. Many intestinal failure patients require PS up to 7 days a week, and sometimes for 20 hours or more per day. While crucial for intestinal failure patients, PS is associated with significant toxicities to patients, similar to some toxicities associated with chemotherapy, often causing serious health problems including infections, metabolic complications, and liver and kidney function problems. These symptoms may emerge at any time in intestinal failure patients and often become life-threatening. "Crofelemer has demonstrated groundbreaking benefit in pediatric IF patients in this study - demonstrating reductions in parenteral support (PS). MVID has a lethal natural history and is an ultrarare pediatric disease, and reduction of PS in MVID patients represents disease progression-modification," said Lisa Conte, Jaguar's president and CEO.
As announced, Dr. Miqdady conducted a presentation at the November 2025 North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting describing the initial groundbreaking results of the investigator-initiated trial in the UAE. Patients participating in the study have now been on crofelemer treatment for more than one year. An abstract to provide an update on the long-term safety and efficacy of crofelemer liquid formulation in pediatric IF patients with MVID and SBS, has been submitted to the ESPGHAN (European Society for Paediatric Gastroenterology Hepatology and Nutrition) Annual Meeting scheduled for June 2026 for consideration for a presentation. The global market for SBS, including IF, is estimated to reach approximately $8.0 billion by 2033.1
The Annual Elite Ped-GI Congress is designed to provide information about high level, clinically significant updates and comprehensive trends relevant to the practice of pediatric gastrointestinal, nutrition and liver disorders. Dr. Miqdady serves as a member of Napo's Scientific Advisory Board. He is an American board-certified pediatric GI, hepatology and nutrition professor at Khalifa University in Abu Dhabi. He completed his Fellowship in Pediatric Gastroenterology at Baylor College of Medicine and Texas Children's Hospital in Houston.
About the Elite Ped-GI Congress
This Elite Ped-GI Congress is designed to provide information about high level, clinically significant updates and comprehensive trends relevant to the practice of pediatric gastroenterological, nutrition and liver disorders. The annual event provides a venue for healthcare professionals to share their best practices, to network within groups of interest, and to create and strengthen clinical collaborations. Additional information about the Elite Ped-GI Congress can be viewed here on the event website.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Jaguar family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including MVID and short bowel syndrome.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation thatJaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
1Global Short Bowel Syndrome Market - Size, Share, and Forecast (2025-2033)
CONTACT:
[email protected]
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire
O.Larsson--RTC
